In 2013 the ACMG addressed a key question facing those who were creating whole genome and whole exome datasets for individuals as part of clinical diagnostic testing.  The question was, what findings should the data be screened for that were not part of the primary diagnostic intent in creating the dataset.  These efforts have led to an ongoing series of policy and position statements known collectively as the "ACMG Secondary Findings (SF) List" (now in version 3.2).  In 2023 the ACMG Board of Directors commissioned a Population Screening Workgroup to address a distinct question, that is:  if genomic datasets are being created for the purpose of population health screening, then what are the "Primary Findings" (PF) that should be offered back to individuals who participate in this screening.  This session will feature talks from members of the ACMG Populations Screening Workgroup on the efforts behind the creation of the "ACMG Primary Findings (PF) Version 1.0 List".  It is anticipated that the release of the ACMG PF Version 1.0 list will be the initiation of an ongoing and iterative process, that will be informed by evolving evidence and will seek to provide guidance for those around the world who are embarking on the important work of contributing to healthier individuals and healthier populations through DNA-based health screening.  The speakers will address:  the distinction between primary and secondary findings, the history and future of using DNA as a tool for population health screening, the implications of the choice of the molecular technologies employed on the programmatic output of a population screening program, and the importance of aiming to deliver benefits to all members of a population through attention to diversity, equity, and inclusion within screening programs.  In addition the speakers will discuss specific gene-condition pairs that are included in the ACMG PF v1.0 List.